Thyronamine
WikiDoc Resources for Thyronamine |
Articles |
---|
Most recent articles on Thyronamine Most cited articles on Thyronamine |
Media |
Powerpoint slides on Thyronamine |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Thyronamine at Clinical Trials.gov Clinical Trials on Thyronamine at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Thyronamine
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Thyronamine Discussion groups on Thyronamine Patient Handouts on Thyronamine Directions to Hospitals Treating Thyronamine Risk calculators and risk factors for Thyronamine
|
Healthcare Provider Resources |
Causes & Risk Factors for Thyronamine |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Thyronamine refers both to a molecule, and to derivatives of that molecule: a family of decarboxylated and deiodinated metabolites of the thyroid hormones thyroxine (T4) and 3,5,3'-triiodothyronine (T3).
The group includes:
- Thyronamine (T0AM)
- 3-Iodothyronamine (T1AM), which is the most notable one as it is a trace amine found in the nervous system. It is a possible candidate for the natural ligand of the trace amine-associated receptor TAAR1 (TAR1), a G protein-coupled receptor located in the cell membrane.
- 3,5-Diiodothyronamine (T2AM)
- 3,5,3'-Triiodothyronamine (T3AM)